Bruce S. Bochner, MD
Member Profile
Bruce S. Bochner, MD
Northwestern University Feinberg School of Medicine, Chicago, Illinois
My primary research interests focus on Siglec-8, an inhibitory receptor expressed on eosinophils and mast cells, and how it can be targeted for clinical benefit. My primary clinical interests are in eosinophil- (and mast-cell) associated diseases, including hypereosinophilic syndrome.
Specialty
Allergy and immunology; Eosinophil biology; siglecs
Publications
Mao H, Kano G, Hudson SA, Brummet M, Zimmermann N, Zhu Z, Bochner BS. Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen. PLoS One. 2013 Jun 28;8(6):e68143. doi: 10.1371/journal.pone.0068143. Print 2013. PubMed PMID: 23840825; PubMed Central PMCID: PMC3695997.
Kiwamoto T, Brummet ME, Wu F, Motari MG, Smith DF, Schnaar RL, Zhu Z, Bochner BS. Mice deficient in the St3gal3 gene product α2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation. J Allergy Clin Immunol. 2013 Jul 2. doi:pii: S0091-6749(13)00836-1. 10.1016/j.jaci.2013.05.018. [Epub ahead of print] PubMed PMID: 23830412.
Bochner BS, Book W, Busse WW, Butterfield J, Furuta GT, Gleich GJ, Klion AD, Lee JJ, Leiferman KM, Minnicozzi M, Moqbel R, Rothenberg ME, Schwartz LB, Simon HU, Wechsler ME, Weller PF. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol. 2012 Sep;130(3):587-96. doi: 10.1016/j.jaci.2012.07.024. PubMed PMID: 22935587; PubMed Central PMCID: PMC3432981.
Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012 Sep;135(3):327-36. doi: 10.1016/j.pharmthera.2012.06.005. Epub 2012 Jun 27. Review. PubMed PMID: 22749793; PubMed Central PMCID: PMC3587973.